Lonza announced on April 4, 2023 an agreement with ABL Bio, a Korean biologics company with a focus on bispecific antibodies for immune-oncology and neurodegenerative diseases. The collaboration agreement between the two companies supports the development and manufacturing of ABL Bio’s new bispecific antibody product.  Source: Biopharm International 7/4/2023